Is GHK-Cu legal in New Zealand?
A plain-language look at how GHK-Cu (copper tripeptide-1) sits within New Zealand's Poisons Standard, the ARTG, and the gap between a cosmetic skincare ingredient and a research compound supplied for laboratory use. General information only, not legal or medical advice.
The short answer
GHK-Cu, also written as copper tripeptide-1 or copper peptide GHK, is not specifically listed by name in the current Poisons Standard (the SUSMP) as a scheduled substance. That is the Therapeutic Goods Administration's own stated position. It is important to understand what this does and does not mean. The absence of a specific schedule entry is not the same as approval, endorsement, or a finding that any GHK-Cu product is safe for use in people.
At the same time, there is no GHK-Cu medicine entered on the New Zealand Register of Therapeutic Goods (ARTG). The TGA has publicly named GHK-Cu among examples of unapproved peptide products that are promoted online, often in injectable form. So the accurate way to describe the situation is this: GHK-Cu is not individually scheduled, but it is also not an approved therapeutic good in New Zealand.
Copper tripeptide-1 appears as an ingredient in some topical cosmetic formulations, which sit under a different regulatory framework to injectable or ingestible products marketed for a therapeutic effect. The regulatory answer depends heavily on the product form and the claims made about it.
What GHK-Cu is
GHK-Cu is a small peptide, a short chain of three amino acids (glycine, histidine and lysine) bound to a copper ion, which is why it is often called a copper tripeptide. The INCI name used on cosmetic ingredient lists is copper tripeptide-1. In a research context it is typically supplied as a lyophilised (freeze-dried) powder intended to be handled in a laboratory setting.
The same chemical name can therefore describe two very different commercial realities. One is a cosmetic raw material formulated into topical skincare products. The other is a stand-alone research compound sold in vials. This guide does not make any claim about what GHK-Cu does in either context. The focus here is strictly on regulatory classification in New Zealand.
Is GHK-Cu named in the Poisons Standard?
The Poisons Standard, formally the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP), is the document that assigns substances to schedules in New Zealand. A schedule determines how a substance may be supplied, for example whether it is a pharmacy-only medicine, a prescription-only medicine, or more tightly controlled.
According to the TGA, GHK-Cu is not specifically scheduled in the Poisons Standard. In practice this means it does not currently have a dedicated entry assigning it to Schedule 4 or any other specific schedule by name. The TGA is explicit that this does not imply the substance is approved or safe for human use, and it does not override the broader rules that apply to therapeutic goods.
Regulatory status can change. Scheduling decisions are reviewed over time, so a substance that is not specifically named today may be considered for scheduling in future. Always check the current Poisons Standard and TGA sources for the latest position rather than relying on a point-in-time summary.
ARTG status: no registered GHK-Cu medicine
The ARTG is the central register of therapeutic goods that may lawfully be supplied in New Zealand. As a general rule, a therapeutic product must be included in the ARTG, or otherwise lawfully supplied through a recognised access pathway, before it can be marketed for use in people.
Searches of the register do not return a GHK-Cu medicine, and the TGA has listed GHK-Cu among unapproved peptide products. Because it has not been entered on the ARTG, it has not been evaluated by the TGA for quality, safety, or effectiveness as a therapeutic good. It is also generally unlawful to advertise therapeutic goods that are not included in the ARTG.
Cosmetic ingredient versus research compound
The single most important nuance with GHK-Cu is that the same name covers two different product categories that are regulated differently. Grouping them together is where a lot of confusion comes from.
Two different contexts for the same name
- Topical cosmetic ingredient: copper tripeptide-1 appears in some leave-on and rinse-off skincare formulations. In New Zealand, cosmetics are generally regulated as industrial chemicals rather than as therapeutic goods, provided the product is used topically and is not marketed with therapeutic claims. A product that crosses into therapeutic claims can be treated as a therapeutic good and attract TGA oversight.
- Research compound: GHK-Cu supplied as a stand-alone lyophilised peptide in vials, often described for laboratory or research use, is not an approved therapeutic good. It is not on the ARTG, has not been assessed for human use, and is not sold on the basis that it is safe or effective for people.
- Claims change everything: the way a product is presented and advertised is central. A topical cosmetic that stays within cosmetic claims is treated differently to any product promoted for a therapeutic purpose, regardless of the chemistry being similar.
This is why a copper peptide serum on a beauty shelf and a vial of research-grade GHK-Cu are not in the same regulatory bucket, even though a label might show the same core ingredient name.
What research use only means here
When GHK-Cu is offered as a research compound, it is supplied on a research-use-only basis. That framing is not a marketing flourish. It reflects the regulatory reality that the material has not been approved for use in people and is intended to be handled in a controlled laboratory setting by appropriately qualified individuals.
On a research-use-only basis, no therapeutic benefit, dosing guidance, or human-use instruction is provided or implied. Nothing in this guide should be read as encouragement to use GHK-Cu in or on the body. The TGA has stated that research-grade products are not approved for human use and that supplying them for use in people may be unlawful.
Not being specifically scheduled is not the same as being approved. The two questions, is it scheduled and is it an approved therapeutic good, have different answers for GHK-Cu.
Sport and anti-doping considerations
Athletes who are subject to anti-doping rules are governed by the World Anti-Doping Agency (WADA) Prohibited List, administered in New Zealand by Sport Integrity New Zealand. GHK-Cu is not clearly named as a specific entry on the list in the sources reviewed, but the Prohibited List includes a broad category, S0, that captures substances with no current approval for human therapeutic use by a government regulatory health authority.
Because GHK-Cu is an unapproved substance, athletes cannot assume it is permitted. The safest course for anyone bound by anti-doping rules is to contact Sport Integrity New Zealand directly before considering any peptide, rather than relying on a general web summary. This guide does not provide anti-doping advice.
How this compares to scheduled peptides
It helps to contrast GHK-Cu with a peptide that is specifically scheduled. BPC-157, another peptide widely discussed online, has been classified by the TGA as a prescription-only medicine (Schedule 4) and is also listed in Appendix D of the Poisons Standard. It has not been approved for human therapeutic use and is not on the ARTG.
GHK-Cu sits in a different position: it is not specifically scheduled by name, yet it is also not an approved therapeutic good. So the comparison is not that one is legal and the other is not. Rather, they occupy different points on the regulatory map, and neither is an approved medicine in New Zealand. Anyone comparing peptides should look at each substance individually against current primary sources.
This article is general information about regulatory classification and is not legal or medical advice. Regulatory status can change. For decisions, consult the current Poisons Standard, the ARTG, the TGA, Sport Integrity New Zealand, or a qualified professional.
Frequently asked questions
Is GHK-Cu specifically banned in New Zealand?+
GHK-Cu is not specifically listed by name as a scheduled substance in the current Poisons Standard, according to the TGA. That is not the same as being approved. There is no GHK-Cu medicine on the ARTG, and the TGA has named it among unapproved peptide products. Always check current sources, as regulatory status can change.
Why is copper peptide in skincare but GHK-Cu called unapproved?+
Topical cosmetics containing copper tripeptide-1 are generally regulated as industrial chemicals when used topically without therapeutic claims. A stand-alone GHK-Cu research compound supplied for laboratory use, or any product marketed with therapeutic claims, is treated differently and is not an approved therapeutic good.
Is GHK-Cu on the ARTG?+
No GHK-Cu therapeutic product was identified on the New Zealand Register of Therapeutic Goods. Because it is not registered, it has not been evaluated by the TGA for quality, safety, or effectiveness as a therapeutic good, and advertising unregistered therapeutic goods is generally unlawful.
Does research use only mean it is approved for people?+
No. Research use only means the material is intended to be handled in a laboratory setting and is not approved for use in people. No therapeutic benefit, dosing, or human-use instruction is provided or implied. The TGA has stated that research-grade products are not approved for human use.
How is GHK-Cu different from BPC-157?+
BPC-157 is classified by the TGA as a prescription-only medicine (Schedule 4) and is listed in Appendix D of the Poisons Standard. GHK-Cu is not specifically scheduled by name. Neither is an approved therapeutic good on the ARTG, so they sit at different points on the regulatory map.
Can athletes use GHK-Cu?+
Athletes subject to anti-doping rules should not assume GHK-Cu is permitted. As an unapproved substance it may fall within the broad S0 non-approved substances category of the WADA Prohibited List. Contact Sport Integrity New Zealand directly before considering any peptide.
Could the legal status of GHK-Cu change?+
Yes. Scheduling decisions are reviewed over time, so a substance that is not specifically named today may be considered for scheduling in future. For the current position, check the live Poisons Standard, the ARTG, and TGA sources rather than relying on any single summary.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp